A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
dc.contributor.author | Sternberg, C | |
dc.contributor.author | Hawkins, Robert E | |
dc.contributor.author | Wagstaff, J | |
dc.contributor.author | Salman, P | |
dc.contributor.author | Mardiak, J | |
dc.contributor.author | Barrios, C | |
dc.contributor.author | Zarba, J | |
dc.contributor.author | Gladkov, O | |
dc.contributor.author | Lee, E | |
dc.contributor.author | Szczylik, C | |
dc.contributor.author | McCann, L | |
dc.contributor.author | Rubin, S | |
dc.contributor.author | Chen, M | |
dc.contributor.author | Davis, I | |
dc.date.accessioned | 2013-05-20T12:42:38Z | |
dc.date.available | 2013-05-20T12:42:38Z | |
dc.date.issued | 2013-04 | |
dc.identifier.citation | A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. 2013, 49 (6):1287-96 Eur J Cancer | en_GB |
dc.identifier.issn | 1879-0852 | |
dc.identifier.pmid | 23321547 | |
dc.identifier.doi | 10.1016/j.ejca.2012.12.010 | |
dc.identifier.uri | http://hdl.handle.net/10541/292373 | |
dc.description.abstract | In this randomised phase III study (VEG105192; NCT00334282), pazopanib previously demonstrated statistically and clinically meaningful improvement of progression-free survival versus placebo in patients with advanced/metastatic renal cell carcinoma (mRCC). Final overall survival (OS) and updated safety results are now reported. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to European journal of cancer (Oxford, England : 1990) | en_GB |
dc.title | A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | en |
dc.type | Article | en |
dc.contributor.department | Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. Electronic address: cstern@mclink.it. | en_GB |
dc.identifier.journal | European Journal of Cancer | en_GB |
html.description.abstract | In this randomised phase III study (VEG105192; NCT00334282), pazopanib previously demonstrated statistically and clinically meaningful improvement of progression-free survival versus placebo in patients with advanced/metastatic renal cell carcinoma (mRCC). Final overall survival (OS) and updated safety results are now reported. |